Relay Therapeutics Inc. is a clinical-stage precision medicines company. The Company is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-1971 and RLY-4008, as well as its PI3Kα mutant selective program (RLY-PI3K1047 program). Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008 is designed to be an oral, small molecule, selective inhibitor of fibroblast growth factor receptor two (FGFR2), a receptor tyrosine kinase that is frequently altered in certain cancers